IMMUNOVANT, INC. Research and Development Expense
IMMUNOVANT, INC. (IMVT) reported Research and Development Expense of $37.74 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-04
- IMMUNOVANT, INC. research and development expense for the quarter ending 2022-09-30 was $37.74M, a 76.67% increase year-over-year.
- IMMUNOVANT, INC. research and development expense for the quarter ending 2022-06-30 was $28.43M, a 51.99% increase year-over-year.
- IMMUNOVANT, INC. research and development expense for the quarter ending 2022-03-31 was $31.99M, a 71.83% increase year-over-year.
- IMMUNOVANT, INC. research and development expense for the quarter ending 2021-12-31 was $29.76M, a 41.08% increase year-over-year.
- IMMUNOVANT, INC. research and development expense for fiscal 2022 was $101.81M, a 48.40% increase from fiscal 2021.
- IMMUNOVANT, INC. research and development expense for fiscal 2021 was $68.60M, a 43.14% increase from fiscal 2020.
- IMMUNOVANT, INC. research and development expense for fiscal 2020 was $47.93M, a 86.25% increase from fiscal 2019.
- IMMUNOVANT, INC. research and development expense for fiscal 2019 was $25.73M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $37.74M 10-Q · filed 2022-11-04 | $66.17M 10-Q · filed 2022-11-04 | $98.15M derived: sum of 3 quarters · filed 2022-11-04 | $127.91M derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-06-30 | $28.43M 10-Q · filed 2022-08-05 | $60.41M derived: sum of 2 quarters · filed 2022-08-05 | $90.17M derived: sum of 3 quarters · filed 2022-08-05 | $111.53M derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-03-31 | $31.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | $61.74M derived: sum of 2 quarters · filed 2022-06-08 | $83.10M derived: sum of 3 quarters · filed 2022-11-04 | $101.81M 10-K · filed 2022-06-08 |
| 2021-12-31 | $29.76M 10-Q · filed 2022-02-04 | $51.12M derived: sum of 2 quarters · filed 2022-11-04 | $69.82M 10-Q · filed 2022-02-04 | $88.44M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-09-30 | $21.36M 10-Q · filed 2022-11-04 | $40.07M 10-Q · filed 2022-11-04 | $58.68M derived: sum of 3 quarters · filed 2022-11-04 | $79.77M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $18.70M 10-Q · filed 2022-08-05 | $37.32M derived: sum of 2 quarters · filed 2022-08-05 | $58.41M derived: sum of 3 quarters · filed 2022-08-05 | $70.39M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $18.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | $39.71M derived: sum of 2 quarters · filed 2022-06-08 | $51.68M derived: sum of 3 quarters · filed 2022-06-08 | $68.60M 10-K · filed 2022-06-08 |
| 2020-12-31 | $21.09M 10-Q · filed 2022-02-04 | $33.07M derived: sum of 2 quarters · filed 2022-02-04 | $49.99M 10-Q · filed 2022-02-04 | $64.16M derived: sum of 4 quarters · filed 2022-02-04 |
| 2020-09-30 | $11.98M 10-Q · filed 2021-11-05 | $28.90M 10-Q · filed 2021-11-05 | $43.07M derived: sum of 3 quarters · filed 2021-11-05 | $48.02M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $16.92M 10-Q · filed 2021-08-09 | $31.09M derived: sum of 2 quarters · filed 2021-08-09 | $36.04M derived: sum of 3 quarters · filed 2021-08-09 | $46.37M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | $19.12M derived: sum of 2 quarters · filed 2021-06-01 | $29.45M derived: sum of 3 quarters · filed 2021-06-01 | $47.93M 10-K · filed 2021-06-01 |
| 2019-12-31 | $4.95M 10-Q · filed 2021-02-16 | $15.28M derived: sum of 2 quarters · filed 2021-02-16 | $33.76M 10-Q · filed 2021-02-16 | $41.73M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-09-30 | $10.33M 10-Q · filed 2020-11-12 | $28.81M 10-Q · filed 2020-11-12 | $36.78M derived: sum of 3 quarters · filed 2020-11-12 | $44.46M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $18.48M 10-Q · filed 2020-08-12 | $26.45M derived: sum of 2 quarters · filed 2020-08-12 | $34.13M derived: sum of 3 quarters · filed 2020-08-12 | |
| 2019-03-31 | $7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | $15.65M derived: sum of 2 quarters · filed 2020-06-29 | $25.73M 10-K · filed 2020-06-29 | |
| 2018-12-31 | $7.68M 10-Q · filed 2020-02-14 | $17.76M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |